Pill Identifier App

IPlex Approval History

  • FDA approved: Yes (First approved December 12th, 2005)
  • Brand name: iPlex
  • Generic name: mecasermin rinfabate [rDNA origin]
  • Previous name: SomatoKine
  • Company: Insmed Incorporated
  • Treatment for: Primary IGF-1 Deficiency

iPlex (mecasermin rinfabate) is the human recombinant of the naturally occurring protein complex of insulin-like growth factor-I (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). iPlex is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

FDA Approval History for iPlex

DateArticle
Dec 12, 2005Approval iPlex Insmed Incorporated - Treatment for Severe Primary IGF-1 Deficiency
Oct 25, 2005FDA to Review Insmed's Complete Response to Approvable Letter for iPlex
Oct 17, 2005Insmed Submits Response to FDA Approvable Letter for iPlex
Sep 27, 2005Insmed Receives Approvable Letter for iPlex
Jun 10, 2005FDA Extends PDUFA Date for SomatoKine to October 3, 2005
Mar 10, 2005FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
Jan  3, 2005Insmed Submits New Drug Application -NDA- to Seek Regulatory Approval of SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web3)